[Translation] An open-label, multicenter, dose-escalation and expansion trial evaluating the safety, tolerability, pharmacokinetic profile and preliminary efficacy of SMET12 in combination with toripalimab in patients with EGFR-positive advanced/metastatic solid tumors Phase I/IIa clinical study
主要目的:评价SMET12联合特瑞普利单抗在EGFR阳性晚期/转移性实体瘤患者中的安全性及耐受性。
次要目的:评价SMET12联合特瑞普利单抗在EGFR阳性晚期/转移性实体瘤患者中的药代动力学(PK)、免疫原性和抗肿瘤活性。
[Translation] Main objective: To evaluate the safety and tolerability of SMET12 combined with toripalimab in patients with EGFR-positive advanced/metastatic solid tumors.
Secondary objectives: To evaluate the pharmacokinetics (PK), immunogenicity and antitumor activity of SMET12 combined with toripalimab in patients with EGFR-positive advanced/metastatic solid tumors.